CCHT(SZ:000661) 智通财经网·2025-09-17 11:36Core Viewpoint - Changchun High-tech (000661.SZ) announced a collaboration with Denmark's ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mites (HDM) [1] Group 1: Partnership Details - Changchun Jinsai Pharmaceutical Co., Ltd., a subsidiary of Changchun High-tech, will jointly develop and commercialize ALK's HDM allergen-specific immunotherapy products in China [1] - The collaboration grants Changchun Jinsai exclusive rights to three ALK-developed products in mainland China, including subcutaneous HDM allergen preparations (Acarizax), skin prick test kits (Acarizax), and sublingual tablets (ACARIZAX®) [1] - The partnership agreement is valid until December 31, 2039, and Changchun Jinsai will pay an upfront fee of €32.7 million for the commercialization rights [1]